Proton-pump inhibitors use, and risk of acute kidney injury: A meta-analysis of observational studies

Drug Design, Development and Therapy

Volumn 11, Issue , 2017, Pages 1335-1351

  Yang, Yi ^a   George, Kaisha C ^a   Shang, Wei Feng ^a   Zeng, Rui ^a   Ge, Shu Wang ^a   Xu, Gang ^a  

^a HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

Author keywords

Acute kidney injury; Meta analysis; Proton pump inhibitor; Risk

Indexed keywords

PROTON PUMP INHIBITOR;

ACUTE KIDNEY FAILURE; ARTICLE; DISEASE ASSOCIATION; EVIDENCE BASED MEDICINE; HIGH RISK PATIENT; HUMAN; KIDNEY FUNCTION TEST; META ANALYSIS; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; PATIENT MONITORING; PRESCRIPTION; RISK ASSESSMENT; RISK FACTOR; SYSTEMATIC REVIEW; URINALYSIS; CASE CONTROL STUDY; CHEMICALLY INDUCED; CHEMISTRY; COHORT ANALYSIS;

ACUTE KIDNEY INJURY; CASE-CONTROL STUDIES; COHORT STUDIES; HUMANS; OBSERVATIONAL STUDIES AS TOPIC; PROTON PUMP INHIBITORS; RISK FACTORS;

EID: 85018901894     PISSN: None     EISSN: 11778881     Source Type: Journal    
DOI: 10.2147/DDDT.S130568     Document Type: Article

References (40)

1. Robinson M, Horn J. Clinical pharmacology of proton pump inhibitors: what the practising physician needs to know. Drugs. 2003;63(24):2739–2754.
2. Grace Newsome E; American College of Rheumatology. Guidelines for the management of rheumatoid arthritis: 2002 update. J Am Acad Nurse Pract. 2002;14(10):432–437.
3. Bateman DN, Colin-Jones D, Hartz S, et al. Mortality study of 18,000 patients treated with omeprazole. Gut. 2003;52(7):942–946.
4. Boparai V, Rajagopalan J, Triadafilopoulos G. Guide to the use of proton pump inhibitors in adult patients. Drugs. 2008;68(7):925–947.
5. Yang YX, Lewis JD, Epstein S, Metz DC. Long-term proton pump inhibitor therapy and risk of hip fracture. JAMA. 2006;296(24):2947–2953.
6. Johnstone J, Nerenberg K, Loeb M. Meta-analysis: proton pump inhibitor use and the risk of community-acquired pneumonia. Aliment Pharmacol Ther. 2010;31(11):1165–1177.
7. Ruffenach SJ, Siskind MS, Lien YH. Acute interstitial nephritis due to omeprazole. Am J Med. 1992;93(4):472–473.
8. Christensen PB, Albertsen KE, Jensen P. Renal failure after omeprazole. Lancet. 1993;341(8836):55.
9. O’Donnell D. Acute renal failure due to omeprazole. Med J Aust. 1996;165(4):234–235.
10. Vera Rivera M, Pou Potau M, Botey Puig A. Omeprazole and interstitial nephritis: a reversible cause of acute renal failure. Med Clin (Barc). 2002;118(1):39.
11. Leonard CE, Freeman CP, Newcomb CW, et al. Proton pump inhibitors and traditional nonsteroidal anti-inflammatory drugs and the risk of acute interstitial nephritis and acute kidney injury. Pharmacoepidemiol Drug Saf. 2012;21(11):1155–1172.
12. Klepser DG, Collier DS, Cochran GL. Proton pump inhibitors and acute kidney injury: a nested case-control study. BMC Nephrology. 2013;14:150.
13. Antoniou T, Hollands S, Gomes T, et al. Proton pump inhibitors and the risk of acute kidney injury in older patients: a population-based cohort study. CMAJ Open. 2015;3(2):E166–E171.
14. Lazarus B, Chen Y, Wilson FP, et al. Proton pump inhibitor use and the risk of chronic kidney disease. JAMA Intern Med. 2016;176(2):238–246.
15. Lee J, Mark RG, Celi LA, Danziger J. Proton pump inhibitors are not associated with acute kidney injury in critical illness. J Clin Pharmacol. 2016;56(12):1500–1506.
16. Xie Y, Bowe B, Li T, Xian H, Balasubramanian S, Al-Aly Z. Proton pump inhibitors and risk of incident CKD and progression to ESRD. J Am Soc Nephrol. 2016;27(10):3153–3163.
17. Walls GA, Shee B, O’Connell D, Peterson J, et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. Available from http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp. Accessed 15 March, 2017.
18. Davies HT, Crombie IK, Tavakoli M. When can odds ratios mislead? BMJ. 1998;316(7136):989–991.
19. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ. 2003;327(7414):557–560.
20. Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997;315(7109):629–634.
21. Sierra F, Suarez M, Rey M, Vela MF. Systematic review: proton pump inhibitor-associated acute interstitial nephritis. Aliment Pharmacol Ther. 2007;26(4):545–553.
22. Harmark L, van der Wiel HE, de Groot MC, van Grootheest AC. Proton pump inhibitor-induced acute interstitial nephritis. Br J Clin Pharmacol. 2007;64(6):819–823.
23. Geevasinga N, Coleman PL, Roger SD. Rabeprazole-induced acute interstitial nephritis. Nephrology (Carlton). 2005;10(1):7–9.
24. Geevasinga N, Coleman PL, Webster AC, Roger SD. Proton pump inhibitors and acute interstitial nephritis. Clin Gastroenterol Hepatol. 2006;4(5):597–604.
25. Praga M, Gonzalez E. Acute interstitial nephritis. Kidney Intern. 2010;77(11):956–961.
26. Perazella MA, Brewster UC. Proton pump inhibitors and the kidney: critical review. Clin Nephrol. 2007;68(2):65–72.
27. Simpson IJ, Marshall MR, Pilmore H, et al. Proton pump inhibitors and acute interstitial nephritis: report and analysis of 15 cases. Nephrology. 2006;11(5):381–385.
28. Arora P, Gupta A, Golzy M, et al. Proton pump inhibitors are associated with increased risk of development of chronic kidney disease. BMC Nephrol. 2016;17(1):112.
29. Coca SG, Singanamala S, Parikh CR. Chronic kidney disease after acute kidney injury: a systematic review and meta-analysis. Kidney Intern. 2012;81(5):442–448.
30. Okusa MD, Chertow GM, Portilla D; Acute Kidney Injury Advisory Group of the American Society of N. The nexus of acute kidney injury, chronic kidney disease, and World Kidney Day 2009. Clin J Am Soc Nephrol. 2009;4(3):520–522.
31. Ishani A, Xue JL, Himmelfarb J, et al. Acute kidney injury increases risk of ESRD among elderly. J Am Soc Nephrol. 2009;20(1):223–228.
32. Peng YC, Lin CL, Yeh HZ, Chang CS, Wu YL, Kao CH. Association between the use of proton pump inhibitors and the risk of ESRD in renal diseases: a population-based, case-control study. Medicine (Baltimore). 2016;95(15):e3363.
33. Mazur A, Maier JA, Rock E, Gueux E, Nowacki W, Rayssiguier Y. Magnesium and the inflammatory response: potential physiopathological implications. Arch Biochem Biophys. 2007;458(1):48–56.
34. Wolf FI, Trapani V, Simonacci M, Ferre S, Maier JA. Magnesium deficiency and endothelial dysfunction: is oxidative stress involved? Magnes Res. 2008;21(1):58–64.
35. Matsuzaki H, Ohdachi J, Fuchigami M, et al. Changes in N-acetyl-beta-D-glucosaminidase activity in the urine and urinary albumin excretion in magnesium deficient rats. Biosci Biotechnol Biochem. 2002;66(1):192–194.
36. Kieboom BC, Kiefte-de Jong JC, Eijgelsheim M, et al. Proton pump inhibitors and hypomagnesemia in the general population: a population-based cohort study. Am J Kidney Dis. 2015;66(5):775–782.
37. Forgacs I, Loganayagam A. Overprescribing proton pump inhibitors. BMJ. 2008;336(7634):2–3.
38. Choudhry MN, Soran H, Ziglam HM. Overuse and inappropriate prescribing of proton pump inhibitors in patients with Clostridium difficile-associated disease. QJM. 2008;101(6):445–448.
39. Strid H, Simren M, Bjornsson ES. Overuse of acid suppressant drugs in patients with chronic renal failure. Nephrol Dial Transplant. 2003;18(3):570–575.
40. Bell JS, Blacker N, Leblanc VT, et al. Prescribing for older people with chronic renal impairment. Aust Fam Physician. 2013;42(1–2):24–28.